share_log

12 Health Care Stocks Moving In Monday's After-Market Session

Benzinga Real-time News ·  Jan 23, 2023 16:32

Gainers

  • Axcella Health (NASDAQ:AXLA) shares moved upwards by 49.9% to $0.65 during Monday's after-market session. Today's trading volume for this security ended up closing at 1.2 million shares, which is 180.5 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $47.8 million.
  • CymaBay Therapeutics (NASDAQ:CBAY) stock rose 7.71% to $7.12. Today's trading volume for this security ended up closing at 79.5K shares, which is 10.7 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $602.9 million.
  • NGM Biopharmaceuticals (NASDAQ:NGM) stock rose 7.56% to $5.4. The company's market cap stands at $441.3 million.
  • ThermoGenesis Holdings (NASDAQ:THMO) shares rose 6.61% to $4.19. The market value of their outstanding shares is at $4.3 million.
  • Molecular Templates (NASDAQ:MTEM) shares rose 6.16% to $0.54. The company's market cap stands at $30.1 million.
  • Freeline Therapeutics (NASDAQ:FRLN) shares moved upwards by 5.08% to $0.65. The market value of their outstanding shares is at $42.0 million.

Losers

  • Great Elm Group (NASDAQ:GEG) shares decreased by 5.8% to $2.11 during Monday's after-market session. The company's market cap stands at $63.3 million.
  • Reshape Lifesciences (NASDAQ:RSLS) shares fell 5.22% to $7.27. The market value of their outstanding shares is at $3.5 million.
  • Acorda Therapeutics (NASDAQ:ACOR) stock decreased by 5.0% to $0.94. The market value of their outstanding shares is at $22.8 million.
  • Quanterix (NASDAQ:QTRX) stock fell 4.97% to $13.98. The market value of their outstanding shares is at $518.0 million.
  • Invivyd (NASDAQ:IVVD) stock declined by 4.91% to $1.94. The company's market cap stands at $211.4 million.
  • Achieve Life Sciences (NASDAQ:ACHV) shares fell 4.88% to $4.88. The company's market cap stands at $87.3 million. See Also:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment